By contrast, a pS727-STAT1-resistant state in individuals with relapsing-remitting multiple sclerosis correlates with suboptimal responses to IFN-β therapy (Feng et al., 2002). The gene discussed is STAT1; the disease is relapsing-remitting multiple sclerosis.